PATENT CLAIM ANALYSIS

Application Number: 16414350
Application Type: Utility
Filing Date: 2019-05
Publication Date: 2019-09
Patent Classification: ["424", "499000"]

Abstract:
Presented herein are powder formulations comprising dihydroergotamine (DHE), or a pharmaceutically acceptable salt thereof. In addition to such formulations, also presented herein are methods comprising intranasally administering powder formulations comprising dihydroergotamine, or a pharmaceutically acceptable salt thereof. The presented methods can be used for treating headache, for example, for rapid onset treatment of headache, including migraine, e.g. acute treatment of migraine with or without aura.

Claim (Index 20):
The method of  claim 12 , wherein said pharmaceutical nasal dosage form upon intranasal administration to a human subject provides at least one of the following pharmacokinetic parameters: C max  of at least 900 pg/mL; AUC 0-t  of at least 1000 pg*hr/mL; and AUC 0-inf  of at least 5000 pg*hr/mL.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 100.0
- Lexical Diversity: 1.69565
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12069667', '12839190', '15471334', '12548292', '14921860']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7969012377256869
- 35 USC 102 Novelty (BERT): 0.5206869670200793
- Combined Prediction Score: 0.7692798106551262
- Mean Citation Score: 300.153426
- Max Citation Score: 311.41263
- Similarity Product: 189.69026334328288

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test